Current and future use of angiotensin II receptor blockers in patients with COVID-19
oleh: A. V. Matveev, V. A. Otdelenov, D. A. Sychev
| Format: | Article |
|---|---|
| Diterbitkan: | Izdatelstvo OKI 2020-10-01 |
Deskripsi
No scientific evidence for the negative influence of angiotensin II receptor blockers onto COVID-19 clinical course has been identified so far. Prescribing angiotensin II receptor blockers as COVID-19 pathogenetic therapy could only be considered within clinical trials. Patients who have been taking angiotensin II receptor blockers for approved indications should continue to do so.